Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 238 resultados
LastUpdate Última actualización 22/04/2026 [07:25:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
previousPage Resultados 125 a 150 de 238 nextPage  

SINGLE-STRANDED DNA MOLECULAR RECOGNITION ELEMENTS AGAINST CYANOTOXIN L-BMAA

NºPublicación:  US20260071989A1 12/03/2026
Solicitante: 
UNIV PUERTO RICO [US]
US_20260071989_PA

Resumen de: US20260071989A1

0000 The present disclosure provides aptamers comprising a nucleotide sequence for binding β-N-methylamino-L-alanine (L-BMAA) or an isomer thereof as well as electrochemical aptamer-based sensor (EAB) compositions that include the aptamers. Further, methods of detecting β-N-methylamino-L-alanine (L-BMAA) or an isomer in a sample are also provided in order to identify presence of L-BMAA in the sample.

ANTIBODY-PEPTIDE FUSION PROTEINS FOR TREATING AMYLOID DISORDERS

NºPublicación:  WO2026055521A1 12/03/2026
Solicitante: 
UNIV TENNESSEE RES FOUND [US]
WO_2026055521_PA

Resumen de: WO2026055521A1

Provided herein are amyloid-reactive peptides and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering an antibody-peptide fusion protein.

FRAGMENTOMICS IN CEREBROSPINAL FLUID

NºPublicación:  WO2026051992A1 12/03/2026
Solicitante: 
CENTRE FOR NOVOSTICS [CN]
WO_2026051992_A1

Resumen de: WO2026051992A1

Various embodiments are directed to the analysis of fragmentation patterns of cell-free DNA (cfDNA) circulating in cerebrospinal fluid (CSF) and the potential applications. CSF is an important liquid biopsy sample used to study the central nervous system and related disorders, such as infection and malignancies. The characterization of fragmentation patterns of cfDNA in CSF includes the size profile, end motif, cleavage profiles, and the determination of epigenetic features, including methylation. Various applications can use one or more properties of fragmentation pattern, for example, in the determination of the proportional contribution of a particular cell types in the CSF cfDNA pool. Another purpose is the diagnosis of pathology in the central nervous system, by the detection of clinically relevant DNA (e.g., tumor fraction, pathogen). DNA fragments in CSF can be analyzed in various ways, including using short-read sequencing, and/or long-read sequencer technologies.

BIOMARKERS FOR DETECTING AND/OR DETERMINING A TREATMENT REGIMEN FOR ALZHEIMER'S DISEASE

NºPublicación:  US20260072043A1 12/03/2026
Solicitante: 
SEQ BIOMARQUE LLC [US]
Seq Biomarque, LLC
US_20260072043_PA

Resumen de: US20260072043A1

The present disclosure provides methods for diagnosing or determining susceptibility to Alzheimer's Disease a subject by obtaining a biological sample from the subject; detecting one or more biomarkers in the biological sample selected from the group consisting of: inflammation biomarkers, oxidative stress biomarkers, insulin resistance biomarkers, and autophagy biomarkers; and diagnosing the subject with Alzheimer's Disease where one or more of the biomarkers is detected in the biological sample. Also provided are methods of treating a subject with Alzheimer's Disease comprising administering to the subject an effective amount of one or more agents for the treatment of inflammation, oxidative stress, insulin resistance, and/or autophagy.

PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASES COMPRISING HIGHLY POTENT STEM CELLS EXPRESSING TIMP-1, MCP-1, GROa, AND IL-6, AND METHOD FOR SELECTING HIGHLY POTENT STEM CELLS

NºPublicación:  US20260072014A1 12/03/2026
Solicitante: 
MEDINNO INC [KR]
US_20260072014_PA

Resumen de: US20260072014A1

The present invention relates to a method for selecting highly potent stem cells for the treatment of neurological disease using TIMP-1, MCP-1, GROα, and IL-6, and a pharmaceutical composition for the prevention or treatment of neurological disease. According to the present invention, a specific combination of markers including TIMP-1, MCP-1, GROα, and IL-6 can be used as a biomarker for selecting stem cells with superior therapeutic (ameliorating) potential in the treatment of neurological disease. Moreover, the application of stem cells exhibiting increased expression or activity of TIMP-1, MCP-1, GROα, and IL-6 factors or the use of substances that regulate (particularly upregulate) these factors in stem cells has a remarkable therapeutic effect on neurological disease due to having high efficacy (potency) and efficiency. Furthermore, the present invention presents the higher therapeutic potential of allogeneic stem cell transplantation.

METHOD FOR MEASURING CELL FREE CHROMATIN

NºPublicación:  US20260072040A1 12/03/2026
Solicitante: 
BELGIAN VOLITION SRL [BE]
Belgian Volition SRL
US_20260072040_A1

Resumen de: US20260072040A1

The invention relates to methods and uses of cell free histone H3 isoforms H3.1, H13.2, H3t and/or H3.3 (or cell free nucleosomes containing said isoforms) of determining the origin of a cell free histone or cell free nucleosome in a body fluid sample as originating from a dividing or non-dividing cell.

METHOD FOR DETECTING LYSOSOMAL STORAGE DISEASE BIOMARKERS AND KITS FOR PERFORMING THE METHOD

NºPublicación:  US20260072045A1 12/03/2026
Solicitante: 
UNIV ANTWERPEN [BE]
UNIV ZIEKENHUIS ANTWERPEN [BE]
US_20260072045_PA

Resumen de: US20260072045A1

The present invention provides methods for detecting multiple biomarkers indicative for lysosomal storage diseases from a dried blood spot. In particular, the present invention provides a method that is suited for detecting multiple biomarkers, each indicative for the presence of a distinct lysosomal storage disease in a subject, based on a single sample preparation procedure. In particular, the method allows simultaneous extraction of different biomarkers such as Lyso-Gb1 (GlcSph). Lyso-Gb3, and others from a dried blood spot sample. The invention further provides a kit of parts comprising means for conducting the methods subject of the invention. Finally, the invention provides a set of reference ranges for Lyso-Gb1 (GlcSph) and Lyso-Gb3 in healthy subjects starting from dried blot spot samples.

METHODS AND COMPOSITIONS FOR T CELL THERAPY

NºPublicación:  US20260072034A1 12/03/2026
Solicitante: 
KITE PHARMA INC [US]
US_20260072034_PA

Resumen de: US20260072034A1

0000 The disclosure relates to methods of diagnosis and prognosis, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same

Universal Efficient Dextran Microparticles Production with Microfluidic Technology

NºPublicación:  US20260071176A1 12/03/2026
Solicitante: 
SANOFI SA [FR]
PASTEUR INSTITUT [FR]
COMMISSARIAT ENERGIE ATOMIQUE [FR]
US_20260071176_PA

Resumen de: US20260071176A1

0000 The present invention relates to the use of modified dextran hydrogel microparticles comprising (i) at least one vinyl sulfone functionalized dextran, and (ii) at least one crosslinkable polymer having at least two thiol functions, wherein the dextran has a molecular weight comprised between 5 and 500 kDa, and the substitution degree of the dextran by the vinyl sulfone is comprised between 5 and 60%, for encapsulating at least one synthetic or natural cell. The present invention also relates to modified dextran hydrogel microparticles, a process for preparing them, an in vitro method for cultivating at least one cell comprised in said microparticles, in vitro methods for screening, for producing or for testing compounds, a kit, a microfluidic or millifluidic channel, a process for encapsulating said microparticles, and a method for the quality control of a batch. Said microparticles are useful in the field of biological and medical applications.

SOLID-PHASE CARRIER FOR DETECTING OR SEPARATING/PURIFYING CELLS AND/OR EXTRACELLULAR VESICLES

NºPublicación:  US20260072026A1 12/03/2026
Solicitante: 
RNAI INC [JP]
US_20260072026_A1

Resumen de: US20260072026A1

The purpose of the present invention is to provide a new technique for trapping cells and/or extracellular vesicles (EVs) without using antibodies. The present invention is a solid-phase carrier having an ability to adsorb cells and/or extracellular vesicles, and comprising a substrate and an ion exchanger.

METHODS OF USING NEUROFILAMENT LIGHT CHAIN IMMUNOASSAYS

NºPublicación:  AU2024366503A1 12/03/2026
Solicitante: 
SIEMENS HEALTHCARE DIAGNOSTICS INC
SIEMENS HEALTHCARE DIAGNOSTICS INC
AU_2024366503_PA

Resumen de: AU2024366503A1

Methods, kits and compositions of detecting analytes, typically analytes relevant to neurodegenerative diseases such as neurofilament light chain, in a sample are described herein using chemiluminescent labels. Solid supports, reagents, and compounds for use in these methods are also described. Typically, the methods involve specific assay formats which provide the requisite high resolution for detecting low concentrations of analytes in samples and may be used in positions of the healthcare ecosystem close to the patient. These methods, systems, and apparatuses may afford early detection and prognosis of a wide variety of neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.

DEVICE FOR PERSONAL PREDICTIVE ENRICHMENT OF A BIOMARKER AND METHODS OF USE THEREOF

NºPublicación:  US20260072023A1 12/03/2026
Solicitante: 
KELLY SEAN M [US]
US_20260072023_PA

Resumen de: US20260072023A1

Methods and devices for enriching a target biomarker from a bodily fluid of a subject are provided. A risk profile for the subject is used to predict that a target biomarker is present in the bodily fluid. The bodily fluid is contacted with a set of immuno-affinity inserts coated with affinity molecules specific for the target biomarker under conditions for the affinity molecules to bind the target biomarker. The affinity molecules bound to the target biomarker are separated from the bodily fluid.

METHODS FOR AIDING IN DIAGNOSING AND EVALUATING A TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING A COMBINATION OF GFAP AND UCH-L1

NºPublicación:  US20260072042A1 12/03/2026
Solicitante: 
ABBOTT LAB [US]
US_20260072042_PA

Resumen de: US20260072042A1

0000 Disclosed herein are methods of aiding in the diagnosis and evaluation of a subject that has sustained or may have sustained an injury to the head. For example, the present disclosure provides methods for aiding in the diagnosis and evaluation of a subject to determine whether the subject has sustained a traumatic brain injury (TBI) by detecting or measuring a combination of the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) in samples taken at various time points within 48 hours after the subject has sustained or may have sustained an injury to the head.

METHOD OF DETERMINING THE PRESENCE OR ABSENCE OF A TARGET ANALYTE COMPRISING USING A REPORTER POLYNUCLEOTIDE AND A TRANSMEMBRANE PORE

NºPublicación:  US20260072019A1 12/03/2026
Solicitante: 
OXFORD NANOPORE TECH PLC [GB]
US_20260072019_PA

Resumen de: US20260072019A1

The invention relates to a method of determining the presence or absence of a target analyte in a sample. The method comprises immobilising any target analyte present in the sample on a surface; contacting the surface with: (i) a first detection agent that binds specifically to the target analyte; and (ii) a reporter polynucleotide, wherein the reporter polynucleotide is bound to, or binds to, the first detection agent; and contacting a transmembrane pore with any reporter polynucleotide that has been immobilised on the surface, wherein the reporter polynucleotide is immobilised on the surface by binding of the first agent to the target analyte, and using the transmembrane pore to detect the reporter polynucleotide, thereby determining the presence or absence of the target analyte in the sample.

Protein biomarkers for diseases associated with the contact activation system

NºPublicación:  AU2026201253A1 12/03/2026
Solicitante: 
TAKEDA PHARMACEUTICALS CO [JP]
AU_2026201253_A1

Resumen de: AU2026201253A1

Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system. eb e b

Nutritive Polypeptides and Formulations Thereof, and Methods of Production and Use Thereof

NºPublicación:  US20260069656A1 12/03/2026
Solicitante: 
AXCELLA HEALTH INC [US]
US_20260069656_A1

Resumen de: US20260069656A1

0000 Nutritive Polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions and formulations that comprise the polypeptides, and methods of using the polypeptides, compositions and formulations.

TRAFFICKED RNAS FOR ASSESSMENT OF CELL-CELL CONNECTIVITY AND NEUROANATOMY

NºPublicación:  US20260071269A1 12/03/2026
Solicitante: 
BROAD INST INC [US]
MASSACHUSETTS GEN HOSPITAL [US]
HARVARD COLLEGE [US]
US_20260071269_PA

Resumen de: US20260071269A1

0000 The present disclosure relates to compositions and methods for tracking and spatially localizing a cell-expressed fusion protein within the cell (with the fusion protein optionally associated with a subcellular compartment, organelle, synapse, or the like), in a manner that minimizes any disruptive impact upon the cell, at least until the detection process is initiated. Use of transcriptomics and/or barcode nucleic acid detection is employed to assess both spatial localization of intracellularly tagged fusion proteins and to establish cell-cell connectivity, e.g., in neurons across a synapse, by associating axonal identities with individual neurons at the molecular tag and transcriptome level.

生物学的老化の治療方法

NºPublicación:  JP2026508461A 11/03/2026
Solicitante: 
バイオビー・インコーポレイテッド
JP_2026508461_PA

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

REGULATE GUT MICROBIOTA TO TREAT NEURODEGENERATIVE DISORDERS

NºPublicación:  EP4707410A2 11/03/2026
Solicitante: 
CALIFORNIA INST OF TECHN [US]
EP_4707410_A2

Resumen de: EP4707410A2

0001 Disclosed herein are methods and compositions that can be used to improve motor deficits and neuroinflammation in subjects in need, for example subjects suffering from neurodegenerative disorders (e.g., Parkinson's disease). Also disclosed are methods and compositions that can be used to diagnose neurodegenerative disorders, such as Parkinson's disease.

METHOD FOR THE IN VITRO DIAGNOSIS OF A NEURODEGENERATIVE DISEASE

NºPublicación:  EP4705774A1 11/03/2026
Solicitante: 
UNIV GRENOBLE ALPES [FR]
INST NAT SANTE RECH MED [FR]
Universit\u00E9 Grenoble Alpes,
Institut National de la Sant\u00E9 et de la Recherche M\u00E9dicale
CN_121039498_A

Resumen de: CN121039498A

The present invention relates to a method for the in vitro diagnosis of a neurodegenerative disease in a human or animal individual in the early stage, comprising a step comprising the detection of the presence of at least one marker selected from the group consisting of derived forms of amyloid beta (A beta) peptides, the derivative forms are selected from oligomers of the peptide and pre-fibrotic and fibrotic aggregated forms of the peptide, and derivative forms of a phosphorylated tau protein, and the derivative forms are selected from over-phosphorylated forms of the protein, aggregated forms of the protein and modified phosphorylated tau proteins resulting from one or more post-translational modifications; the presence of a marker is detected in a fecal sample of the individual.

異常タンパク質の蓄積に起因する疾患の予後予測方法

NºPublicación:  JP2026042645A 11/03/2026
Solicitante: 
国立大学法人京都大学
JP_2026042645_A

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

免疫ベースのバイオセンサーを用いたエアロゾル化病原体の電気化学検出

NºPublicación:  JP2026508217A 10/03/2026
Solicitante: 
ワシントン・ユニバーシティ
JP_2026508217_PA

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

ガスダーミンDに対するシングルドメイン抗体およびその使用

NºPublicación:  JP2026508175A 10/03/2026
Solicitante: 
ライニッシュフリードリッヒ-ウィルヘルムズ-ユニバーシタットボン
JP_2026508175_A

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

一种放大信号的全自动免疫检测方法、检测试剂及样本分析仪

NºPublicación:  CN121633467A 10/03/2026
Solicitante: 
深圳市新产业生物医学工程股份有限公司
CN_121633467_A

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

단백질-단백질 상호작용을 유도하는 화합물을 식별하는 방법

Nº publicación: KR20260034056A 10/03/2026

Solicitante:

온코피아테라퓨틱스인코퍼레이티드디비에이에스케이라이프사이언스랩스

KR_20260034056_PA

Resumen de: WO2024263939A1

The present disclosure relates method of identifying a compound targeting a first protein and a second protein, wherein the first protein and/or the second protein are associated with a disease or disorder.

traducir